Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1873 - A randomized comparative study of PF-05280586 (a potential biosimilar) vs rituximab for patients with CD20 + , low tumor burden, follicular lymphoma


08 Oct 2016


Poster Display


Ira Jacobs


Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375


I. Jacobs1, M. Suster2, B. Jin3, D. Yin4, L.A. Melia2

Author affiliations

  • 1 Global Medical Affairs, Pfizer Inc., 10017-5755 - New York/US
  • 2 Biotechnology Clinical Development, Pfizer Inc, San Diego/US
  • 3 Oncology–rinat R&d–therapeutic Vaccines Development Statistics, Pfizer Inc., Cambridge/US
  • 4 Clinical Pharmacology, Pfizer Inc., San Diego/US


Abstract 1873


Use of single-agent rituximab may provide a useful alternative to watchful waiting by delaying the time to initiation of chemotherapy in patients with low tumor burden follicular lymphoma (LTB-FL). However, access to biologics like rituximab can be restricted. Biosimilars to rituximab represent a potential opportunity to increase patient access and lower treatment cost. PF-05280586, a proposed biosimilar to rituximab, has the same primary amino acid sequence, similar physicochemical and in vitro functional properties, and demonstrated similarity to rituximab in nonclinical evaluations and a pharmacokinetics (PK) similarity trial in patients with active rheumatoid arthritis. This confirmatory trial will evaluate efficacy, safety, and immunogenicity of PF-05280586 and rituximab sourced from the EU (rituximab-EU) in patients with treatment-naïve CD20 + , LTB-FL in a monotherapy setting, which allows assessment of biosimilarity without potentially confounding factors such as chemotherapy.

Trial design

Patients (N = 394) will be stratified by risk level and randomized (1:1; double-blind) to 4 weekly doses of IV PF-05280586 or rituximab-EU (375 mg/m2 of body surface area). The primary endpoint is overall response rate at Wk 26. Secondary endpoints include safety, time to treatment failure, progression-free survival, complete remission rate at Wk 26, response duration, overall survival, PK, CD19+ B-cell depletion, and immunogenicity. Eligible patients are ≥18 yrs with histologically confirmed, Grade 1-3a, low tumor burden, CD20+ follicular lymphoma with no elements of diffuse large B-cell lymphoma; Ann Arbor Stage II, III or IV; and ECOG status of 0-1. Key exclusion criteria are: patients who are not candidates for rituximab monotherapy; evidence of histologic transformation to high-grade or diffuse large B-cell lymphoma; central nervous system, meningeal involvement or cord compression by the lymphoma; ≥5000/mm3 circulating lymphoma cells; prior systemic therapy for lymphoma; prior treatment with rituximab; impaired bone marrow function; symptomatic ischemic heart disease or congestive heart failure; or active uncontrolled infection.

Clinical trial identification


Legal entity responsible for the study

Pfizer Inc.


Pfizer Inc.


I. Jacobs, B. Jin, D. Yin, L.A. Melia: Full time employee of and stock holdings and/or stock options from Pfizer Inc. M. Suster: is a consultant for Pfizer Inc.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings